Core Viewpoint - Guoen Technology is set to launch its global offering on January 27, with a pricing range of HKD 34-42 per share, aiming for a total issuance scale of approximately HKD 10.2 billion to 12.6 billion. The market is discussing the rationality of its pricing, stock price stability post-listing, and long-term valuation logic due to various factors including its business structure and competitive landscape [1][4][11]. Group 1: Financial Performance - Guoen Technology's revenue for 2022-2024 is projected at CNY 134 billion, CNY 174 billion, and CNY 192 billion, with a compound annual growth rate (CAGR) of 19.6%. However, growth is expected to slow to 9.9% in the first ten months of 2025 [2][3]. - The company's net profit has shown significant volatility, with figures of CNY 6.6 billion, CNY 4.7 billion, CNY 6.9 billion, and CNY 7.1 billion for the same periods, reflecting fluctuations of 3.1%, -29.7%, 45.2%, and 40.2% respectively [2][3]. Group 2: Cost Structure and Profitability - Raw material costs account for over 90% of sales costs, leading to limited profitability. The gross margin has declined from 11.8% to 8.3% from 2022 to 2024, with a slight recovery to 10.4% in the first three quarters of 2025 [3][11]. - The health sector shows stronger profitability potential, with a gross margin of 22.5% in the first ten months of 2025, but its revenue contribution is only 3.5%, insufficient to offset the low margins from the chemical sector [3][11]. Group 3: Market Position and Investor Interest - Guoen Technology's market capitalization of CNY 151 billion is the smallest among five concurrent A to H projects, which may reduce its attractiveness to institutional investors [4][5]. - The company has attracted eight cornerstone investors, raising USD 4.1 million, with significant investments from local and health-focused entities, indicating a strategic interest in its health sector [6][8]. Group 4: Market Dynamics and Risks - The absence of a greenshoe option in the offering raises concerns about stock price stability post-listing, as it lacks market support mechanisms [9][10]. - The Hong Kong market's preference for high-growth sectors may limit Guoen Technology's valuation, as its chemical business faces inherent valuation discounts compared to high-margin sectors [11].

Core Viewpoint - The Hong Kong IPO market experienced a strong recovery in the first half of 2025, with 42 companies raising a total of HKD 1,067 billion, marking a 688% increase compared to the same period in 2024, and surpassing the total from 2022 to 2024 [1] Group 1: A to H Companies - Over 70 A-share companies have announced plans to list on the Hong Kong Stock Exchange since 2024, with 7 companies completing their IPOs in the first half of 2025, raising over HKD 770 billion, accounting for 72% of the total IPO amount [1] - The IPO issuance discount for A to H projects is positively correlated with company market capitalization, where larger A-share companies attract more investor interest, resulting in lower issuance discounts; for instance, CATL's Hong Kong issuance price was only 6.8% lower than its A-share price [1] - Despite the strong fundraising from A to H projects, the first-day drop rate reached 57%, with four companies experiencing a drop below their issuance price, including Haitian Flavoring and Sanhua Intelligent Control [1] Group 2: Industry Performance - The consumer discretionary sector emerged as the most active segment, with 7 IPOs raising HKD 105.7 billion, led by Mixue Ice City, which raised HKD 39.7 billion with a subscription rate of 5,258.2 times, freezing HKD 1.8 trillion [1] - The innovative drug sector, with 5 IPOs raising HKD 40.6 billion, became the most profitable segment, achieving an average increase of 78.4% since listing, with some companies like InnoCare Pharma and Brainhole achieving over 100% excess returns [1] - The industrial materials sector, along with information technology and finance, showed a downturn, contributing only 19 IPOs, which accounted for 45.2% of the total, but with a significantly lower actual fundraising scale [1]